Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Eliquis

Bristol-Myers Squibb (BMS) building

BMS gets two new cancer approvals in Europe

Empliciti, and Opdivo and Yervoy inhibitor combination get the green light

Bristol-Myers Squibb (BMS) building

BMS claims 80% market share for Opdivo in US

New indications and label updates boost the cancer immunotherapy’s market position

Bristol Myers Squibb logo

Opdivo boosts survival in head and neck cancer by 30%

Pivotal trial of BMS’ PD-1 inhibitor shows "significant benefit" in overall survival

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo gets two new indications in Europe

Receives green light as lung and kidney cancer immunotherapy

- PMLiVE

GSK gene therapy tops CHMP recommendations

ADA-SCID treatment Strimvelis set for European approval

Bristol Myers Squibb logo

Opdivo edges closer to first haematological cancer indication

EMA begins review of BMS' classic Hodgkin’s lymphoma inhibitor treatment

- PMLiVE

BMS appoints Peter Arduini to board of directors

He brings experience from Integra LifeSciences and Baxter Healthcare

Bristol Myers Squibb logo

Opdivo backed for two new uses by CHMP

Recommended for additional European approvals in kidney cancer and NSCLC

EU flag

CHMP backs orphan drugs Uptravi and Coagadex

EMA advisors set Actelion and Bio Products therapies on path to European approval

- PMLiVE

Empliciti on track for European approval in multiple myeloma

CHMP backs BMS and AbbVie's therapy after an accelerated assessment

National Institute for Health and Care Excellence NICE logo

NICE backs BMS’ Opdivo for melanoma

Recommendation comes despite the Institute rejecting the drug for lung cancer

Brain cancer glioblastoma

Glioblastoma market set for ‘meteoric rise’

Sales of treatments for rare brain cancer predicted to reach $3.3bn by 2024

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links